4 - Longview Acquisition Corp. II (0001832300) (Issuer)

On December 14, 2022, Longview Acquisition Corp. II ("Longview" or "the Company") (NYSE:LGV, LGV and LGV WS))) stockholders approved (i) an amendment to Longview's Amended and Restated Certificate of Incorporation (the "Charter") (and the Charter, as amended, the "Second Amended and Restated Certificate of Incorporation") and (ii) and an amendment to Longview's Investment Trust Management Agreement, dated March 18, 2021, by and between the Company and Continental Stock Transfer & Trust Company, a New York limited purpose trust company ("Continental"), as trustee (the "Amendment to the Investment Trust Management Agreement") to allow Longview to (i) change the date by which the Company must

REDWOOD CITY, Calif., Feb. 04, 2022 (GLOBE NEWSWIRE) -- HeartFlow Holding, Inc. ("HeartFlow"), the leader in revolutionizing precision heart care, today announced that it and Longview Acquisition Corporation II (NYSE:LGV), a special purpose acquisition company sponsored by affiliates of Glenview Capital Management, LLC, have mutually agreed to terminate their previously announced business combination agreement, effective immediately, as a result of current unfavorable market conditions.  About HeartFlowHeartFlow is the leader in revolutionizing precision heart care, uniquely combining human ingenuity with advanced technology. HeartFlow's non-invasive HeartFlow FFRct Analysis leverages art

Transforming the way heart disease is diagnosed and treated, HeartFlow's artificial intelligence-enabled software platform brings precision heart care to cardiology. The HeartFlow Analysis is the first and only non-invasive tool to assist with the diagnosis, management and treatment of patients with heart disease, the most common type of cardiovascular disease which accounts for one in three deaths and $1 out of every $6 of U.S. healthcare spend1. HeartFlow has demonstrated higher diagnostic accuracy compared to other non-invasive tests2 with an 83% reduction in unnecessary invasive angiograms, resulting in a significant reduction in the total cost of care3. Merging with Longview Acq

15-12G - Longview Acquisition Corp. II (0001832300) (Filer)

25-NSE - Longview Acquisition Corp. II (0001832300) (Subject)

8-K - Longview Acquisition Corp. II (0001832300) (Filer)

8-K - Longview Acquisition Corp. II (0001832300) (Filer)

8-K - Longview Acquisition Corp. II (0001832300) (Filer)

DEF 14A - Longview Acquisition Corp. II (0001832300) (Filer)

10-Q - Longview Acquisition Corp. II (0001832300) (Filer)

8-K - Longview Acquisition Corp. II (0001832300) (Filer)

RW - Longview Acquisition Corp. II (0001832300) (Filer)

PRE 14A - Longview Acquisition Corp. II (0001832300) (Filer)

Transforming the way heart disease is diagnosed and treated, HeartFlow's artificial intelligence-enabled software platform brings precision heart care to cardiology. The HeartFlow Analysis is the first and only non-invasive tool to assist with the diagnosis, management and treatment of patients with heart disease, the most common type of cardiovascular disease which accounts for one in three deaths and $1 out of every $6 of U.S. healthcare spend1. HeartFlow has demonstrated higher diagnostic accuracy compared to other non-invasive tests2 with an 83% reduction in unnecessary invasive angiograms, resulting in a significant reduction in the total cost of care3. Merging with Longview Acq

SC 13G/A - Longview Acquisition Corp. II (0001832300) (Subject)

SC 13G - Longview Acquisition Corp. II (0001832300) (Subject)